Resection of solid tumors reverses T cell defects and restores protective immunity

Journal of Immunology

Volumn 164, Issue 4, 2000, Pages 2214-2220

  Salvadori, Silvia ^a   Martinelli, Giorgio ^a   Zier, Karen ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; CANCER IMMUNOLOGY; CANCER SURGERY; CYTOTOXIC T LYMPHOCYTE; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0034651585     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.4.2214     Document Type: Article

References (40)

1. Mizoguchi, H., J. J. O'Shea, D. L. Longo, C. M. Loeffler, D. W. McVicar, and A. C. Ochoa. 1992. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795.
2. Salvadori, S., B. Gansbacher, A. M. Pizzimenti, and K. S. Zier. 1994. Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice hearing IL-2 secreting tumors. J. Immunol. 153:5176.
3. Chambers, C. A., and J. P. Allison. 1996. The role of tyrosine phosphorylation and PTP-IC in CTLA-4 signal transduction. Eur. J. Immunol 26:3224.
4. Watson, A. G., and D. M. Lopez. 1995. Aberrant antigen presentation by macrophages from tumor bearing mice is involved in the down-regulation of their T cell responses. J. Immunol 155:3124.
5. Ganshacher, B., K. Zier, B. Daniels, K. Cronin, R. Bannerji, and E. Gilboa. 1990. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172:1217.
6. Salvadori, S., and K. Zier. 1996. The molecular basis of T cell dysfunction in cancer is influenced by the paracrine secretion of tumor-derived IL-2. J. Immunol. 156:2927.
7. Sloan-Lancaster, J., A. S. Shaw, J. B. Rothbard, and P. M. Allen. 1994. Partial T cell signaling: altered phospho-ζ and lack of ZAP-70 recruitment in APL-induced T cell anergy. Cell 79:913.
8. Madrenas, J., R. L. Wange, J. L. Wang, N. Isakov, L. E. Samelson, and R. N. Germain. 1995. ζ Phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists. Science 267:515.
9. Wallich, R., N. Bulbuc, G. J. Hammerling, S. Katzav, S. Segal, and M. Feldman. 1985. Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315:301.
10. DeLeo, A. B., H. Shiku, T. Takahashi, M. John, and L. J. Old. 1977. Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblast and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma. J. Exp. Med. 146:720.
11. Pardoll, D. M. 1995. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13:399.
12. Bruce, J., F. W. Symington, T. J. McKean, and J. Sprent. 1981. A monoclonal antibody discriminating between subsets of T and B cells. J. Immunol. 127:2496.
13. Zier, K. S., S. Salvadori, C. K. Cronin, and B. Gansbacher. 1994. Vaccination with IL-2-secreting tumor cells stimulates the generation of IL-2-responsive T cells and prevents the development of unresponsiveness. Cancer Gene Ther. 1:43.
14. Aoe, T. Y. Okamoto, and T. Saito. 1995. Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J. Exp. Med. 181:1881.
15. Franco, J. L., P. Ghosh, R. H. Wiltrout, C. L. D. Carter, A. H. Zea, N. Momozaki, A. C. Ochoa, D. L. Longo, T. J. Sayers, and K. L. Komschlies. 1995. Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice. Cancer Res. 55:3840.
16. Otsuji, M., Y. Kimura, T. Aoe, Y. Okamoto, and T. Saito. 1996. Oxidative stress by tumor-derived macrophages suppress the expression of CD3 ζ chain of T-cell receptor complex and antigen-specific T-cell responses. Proc. Natl. Acad. Sci. USA 93:13119.
17. + cells. J. Immunol. 161:5313.
18. + T cell responses by dysregulating antigen-presenting cell maturation. J. Immunol. 162:5728.
19. Watson, A. G., Y.-X. Fu, and D. M. Lopez. 1991. Splenic macrophages from tumor-bearing mice co-expressing MAC-1 and MAC-2 antigens exert immunoregulatory functions via two distinct mechanisms. J. Leukocyte Biol. 49:126.
20. dim lymphocyte populations using two positive selection methods in tandem. J. Immunol. Methods 165:138.
21. Matsuda, M., M. Petersson, R. Lenkei, J.-L. Taupin, I. Magnusson, H. Mellstedt, P. Anderson, and R. Kiessling. 1996. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int. J. Cancer 61:765.
22. + T cells in the antitumor immune response. J. Exp. Med. 188:2357.
23. + T cells. J. Immunol. 149:949.
24. Pericle, F., L. A. Pinto, S. Hicks, R. A. Kirken, G. Sconocchia, J. Rusnak, M. J. Dolan, G. M. Shearer, and D. M. Segal. 1998. HIV-1 infection induces a selective reduction in STAT5 protein expression. J. Immunol. 160:28.
25. Ng, J., and D. Cantrell. 1997. STAT3 is a serine kinase target in T lymphocytes. J. Biol. Chem. 39:24542.
26. Chen, L., S. Ashe, W. A. Brady, I. Hellstrom, K. E. Hellstrom, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093.
27. + T cells by B7-transfected melanoma cells. Science 259:368.
28. Baskar, S., S. Ostrand-Rosenberg, N. Nabavi, L. M. Nadler, G. J. Freeman, and L. H. Glimcher. 1993. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 90:5687.
29. + cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med. 177:1791.
30. Bradley, L. M., M. Croft, and S. L. Swain. 1993. T-cell memory: new perspectives. Imnmnol. Today 14:197.
31. Sulitzeanu, D. 1993. Immunosuppressive factors in human cancer. Adv. Cancer Res. 60:247.
32. Broder, S., and T. A. Waldmann. 1978. The suppressor-cell network in cancer. N. Engl. J. Med. 299:1281.
33. Huang, A. Y. C., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961.
34. Schoenherger, S. P., L. E. Jonges, R. J. D. Mooijaart, F. Hartgers, R. E. M. Toes, W. M. Kast, C. J. M. Melief, and R. Offringa. 1998. Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC. Cancer Res. 58:3094.
35. Salvadori, S., B. Gansbacher, and K. Zier. 1994. Functional defects are associated with abnormal signal transduction in T cells of mice inoculated with parental but not IL-2 secreting tumor cells. Cancer Gene Ther. 1:165.
36. Luo, G., and L. Yu-Lee. 1997. Transcriptional inhibition by Stat5. J. Biol. Chem. 272:26841.
37. Stoppacciaro, A., C. Melani, M. Parenza, A. Mastracchio, C. Bassi, C. Baroni, O. Parmiani, and M. P. Colombo. 1993. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon γ. J. Exp. Med. 178:151.
38. Miller, D. M., B. M. Rahill, J. M. Boss, M. D. Lairmore, J. E. Durbin, W. J. Waldman, and D. D. Sedmak. 1998. Human cytomegalovirus inhibits major histocompalibility complex class II expression by disruption of the Jak/Stat pathway. J. Exp. Med. 187:675.
39. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc. Natal. Acad. Sci. USA 90:3539.
40. Levitsky, H., A. Lazenby, R. J. Hayashi, and D. Pardoll. 1994. In vivo priming of two distinct antitumor effector populations: the role of MHC class 1 expression. J. Exp. Med. 179:1215.